Kevin is the CEO and Managing Director of Keswick pharmaceuticals, which focuses on commercializing Rx pharmaceutical products for areas of unmet or under-met disease states. Kevin has extensive experience as both an entrepreneur and corporate executive with a successful track record of building operating companies. Kevin has created +$2B USD in returns to investors as a founder, operator, and investor, with a heavy focus on pharma and biotech. He was commercial lead for Lanoxin Canada post-2001 GlaxoWellcome acquisition, led acquisition of commercial rights to Cycloset in 2005/6, which eventually sold to Valeant, built the founding team/platform to commercialize FluMist at MedImmune, was part of the founding executive team for Novartis Vaccines post-acquisition of Chiron, led PBM Pharma 2011-14, growing it for $2mn to $80mn and selling to Concordia Healthcare for over $500mn in combined cash/stock, sourced and helped PBM Capital close Avexis 2014 leading to ultimate 2016 Nasdaq listing and 2018 $8.7B sale to Novartis. Kevin obtained his BS from West Virginia University and completed postgraduate studies in marketing at the Kellogg School of Management at Northwestern University. Kevin currently serves as a board member and advisor for Viafy.